ArticleAnnals of medicine2025
Inhibition of 5-hydroxyindoleacetic acid to reduce neutrophil extracellular trap production improves lung condition in chronic obstructive pulmonary disease mice.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cell death crosstalk in NET-Driven inflammation: mechanisms, disease contexts, and therapeutic perspectives.Biomarker research · 2026Review
- Royal Jelly and 10-Hydroxy-2-decenoic Acid Mitigate Alcoholic Fatty Liver Disease in Mice via the Gut-Microbiota-Metabolite Axis.Molecular nutrition & food research · 2026Article
- Neutrophil extracellular traps in asthma and chronic obstructive pulmonary disease: pathogenic roles, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Mitochondrial reprogramming of neutrophil extracellular traps in chronic obstructive pulmonary disease and asthma: toward a phenotype-driven therapeutic framework.Frontiers in immunology · 2026Review
- Gut dysbiosis, metabolic signals, and pulmonary immune reprogramming: decoding the gut microbiota -immune axis in stroke-associated pneumonia.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeutrophil extracellular trap (NET) correlate with chronic obstructive pulmonary disease (COPD) severity. Platelets can promote NET generation. However, serotonin alone or serotonin-deficient platelets do not adequately promote NET production. The metabolism of serotonin to 5-hydroxyindoleacetic acid (5-HIAA) in platelets may be the key to this difference.
objectiveThe study aimed to determine whether 5-HIAA can influence NET production and thus play a role in COPD.
methodsAfter a 4-hour co-incubation with lipopolysaccharide (LPS) and 5-HIAA, NET and ROS levels in the culture medium were measured by ELISA, and NET production with aryl hydrocarbon receptor (AHR) expression in adherent cells were analyzed by immunofluorescence.A COPD model was established in C57BL/6 mice through smoke exposure combined with LPS tracheal administration, followed by selegiline or 5-HIAA treatment. Post-intervention, lung function tests and sample collection were performed. The levels of 5-HIAA, ROS, NET, IL-6, and AHR in the samples were quantified by ELISA, pathological changes were assessed by HE staining, and NET/AHR expression was detected by immunofluorescence.
results5-HIAA promoted NET production
conclusionInhibiting 5-HIAA reduces NET generation, thereby improving lung conditions in COPD mice, which is associated with the 5-HIAA/AHR pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.